The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

Table 3 PAH medication treatment patterns (12 month follow-up)

	PAH subjects ¹(N = 425)
	n	%
Discontinuation of index therapy regimen	162	38.12
Switch from index therapy regimen²	23	14.20
Augmentation to index therapy regimen	47	11.06
Maintenance of index therapy regimen	224	52.71
Medication Possession Ratio (MPR)	n	mean
Bosentan	177	0.94
Ambrisentan	29	0.94
Iloprost	4	0.86
Treprostinil	2	1.00
Epoprostenol	0	-
Tadalafil (Adcirca®)	22	0.94
Sildenafil (Revatio®)	191	0.92

¹Of the subjects in the final sample, 425 were monotherapy pharmacy users in the 30 days following the index date; these subjects were included in the analysis of follow-up treatment patterns.
²Percentage of switchers calculated out of subjects who discontinued (n = 162).

ISSN: 1472-6963